Combining Dalantercept and Axitinib for Advanced Kidney Cancer

Clinical Pearls

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study. The study compareddalantercept plus axitinib with placebo plus axitinib for patients with advanced clear cell renal cell carcinoma.

• Dose-determining toxicities for dalantercept were fluid retention and anemia.
• No additive toxicity was observed. The combination was well tolerated, even at the highest dose levels.
• Median PFS was approximately 8 months for the entire study population.
• Median PFS has not yet been reached among patients receiving the dose chosen for part II of the study.